Stifel Nicolaus Initiates Coverage on COMPASS Pathways (NASDAQ:CMPS)

Stifel Nicolaus began coverage on shares of COMPASS Pathways (NASDAQ:CMPS) in a research note issued to investors on Thursday, Marketbeat.com reports. The brokerage set a “buy” rating and a $11.00 price target on the stock. Stifel Nicolaus’ price target would indicate a potential upside of 179.90% from the company’s previous close.

Several other equities research analysts also recently weighed in on CMPS. Royal Bank of Canada reaffirmed an “outperform” rating and set a $18.00 target price on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Maxim Group cut their target price on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, HC Wainwright cut their target price on shares of COMPASS Pathways from $60.00 to $45.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $21.83.

COMPASS Pathways Price Performance

COMPASS Pathways stock opened at $3.93 on Thursday. The company’s 50 day simple moving average is $4.06 and its 200-day simple moving average is $5.26. The company has a market capitalization of $268.89 million, a price-to-earnings ratio of -1.79 and a beta of 2.28. COMPASS Pathways has a 1 year low of $3.16 and a 1 year high of $12.57. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91.

COMPASS Pathways (NASDAQ:CMPS) last announced its earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.01). As a group, equities research analysts expect that COMPASS Pathways will post -2.33 earnings per share for the current year.

Institutional Investors Weigh In On COMPASS Pathways

Large investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. purchased a new stake in shares of COMPASS Pathways in the 4th quarter valued at approximately $41,000. Wealthfront Advisers LLC purchased a new stake in shares of COMPASS Pathways in the 4th quarter valued at approximately $43,000. Flagship Harbor Advisors LLC purchased a new stake in shares of COMPASS Pathways in the 4th quarter valued at approximately $43,000. Conservest Capital Advisors Inc. increased its position in shares of COMPASS Pathways by 28.9% in the 4th quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock valued at $51,000 after purchasing an additional 3,000 shares during the last quarter. Finally, Simplify Asset Management Inc. acquired a new position in shares of COMPASS Pathways in the 4th quarter valued at $54,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.